Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial - Shenderov - 2021 - The Prostate - Wiley Online Library

Frontiers Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650

Frontiers Adverse Events Following Administration of Anti-CTLA4 Antibody Ipilimumab

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial - ScienceDirect

Ipilimumab - Wikipedia

Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer - ScienceDirect

ASCO GU 2019: Initial Results from a Phase II Study of Nivolumab plus Ipilimumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer - CheckMate 650